Willingness to Pay for an MRNA-based Anti-cancer Treatment: Results from a Contingent Valuation Study in Israel

Overview

Journal Isr J Health Policy Res

Publisher Biomed Central

Specialties Health Services
Public Health

Date 2024 Feb 19

PMID 38374060

Authors

Omer Ben-Aharon

Ruslan Sergienko

Georgi Iskrov

Dan Greenberg

Affiliations

Soon will be listed here.

Abstract

Background: mRNA technology is currently being investigated for a range of oncology indications. We assessed the willingness to pay (WTP) of the general population in Israel for a hypothetical novel mRNA-based treatment for oncology indications.

Methods: We used a contingent valuation methodology to elicit WTP using a web-based questionnaire. A sample of adult participants were presented with a hypothetical scenario in which an mRNA-based intervention increased the likelihood of a cure for various cancer types from 20% to 40% (half of the sample), or 60% (the other half of the sample).

Results: 531 respondents completed the questionnaire. The mean, median and mode WTP for the proposed hypothetical treatment in both scenarios were ILS65,000 (± ILS114,000), ILS20,000 and ILS50,000, respectively (1USD = 3.4ILS). The WTP was skewed towards zero, and 9.6% of the respondents were not willing to pay any amount. WTP higher amounts was significantly associated with higher income (p < 0.01), self-reported good health (p < 0.05), supplementary health insurance (p < 0.05), Jews compared to other populations (p < 0.01), interest in technology (p < 0.001) and a tendency to adopt medical innovations (p < 0.001). No statistical difference between the 40% vs. the 60% potential cure scenarios was found. Logistic and OLS regressions indicated that age, religion, income, and interest in adopting medical innovations were the best predictors of respondents' WTP.

Conclusion: Despite the scientific breakthroughs in oncology treatment over the last few decades, many types of cancer are still incurable. Given the expected development of innovative mRNA-based treatments for cancer, these results should inform policymakers, the pharmaceutical industry and other stakeholders on the future coverage and reimbursement of these technologies incorporating patients' and societal views. To date, WTP considerations have not been given much weight in prioritization of drug reimbursement processes, neither in Israel nor in other countries. As a pioneer in adoption of the mRNA technology, Israel can also lead the incorporation of WTP considerations in this field.

References

Jan M, Fu T, Huang C . Willingness to pay for low-lung-cancer-risk cigarettes in Taiwan. Health Econ. 2004; 14(1):55-67. DOI: 10.1002/hec.894. View

Oh D, Crawford B, Kim S, Chung H, McDonald J, Lee S . Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study. Asia Pac J Clin Oncol. 2012; 8(3):282-91. DOI: 10.1111/j.1743-7563.2012.01546.x. View

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View

Brown D, Reed Johnson F, Poulos C, Messonnier M . Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010; 28(7):1702-8. DOI: 10.1016/j.vaccine.2009.12.024. View

Yasunaga H . Who wants cancer screening with PET? A contingent valuation survey in Japan. Eur J Radiol. 2007; 70(1):190-4. DOI: 10.1016/j.ejrad.2007.11.020. View

Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View

Choi H, Leung G, Woo P, Jit M, Wu J . Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents. Vaccine. 2013; 32(1):78-84. DOI: 10.1016/j.vaccine.2013.10.068. View

Ha T, Van Hoang M, Vu M, Hoang N, Khuong L, Nu Vu A . Willingness to pay for a quality-adjusted life year among advanced non-small cell lung cancer patients in Viet Nam, 2018. Medicine (Baltimore). 2020; 99(9):e19379. PMC: 7478749. DOI: 10.1097/MD.0000000000019379. View

Havet N, Morelle M, Remonnay R, Carrere M . Cancer patients' willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network. Eur J Health Econ. 2011; 13(3):289-300. DOI: 10.1007/s10198-011-0328-9. View

10.

Wagner T, Hu T, Duenas G, Kaplan C, Nguyen B, Pasick R . Does willingness to pay vary by race/ethnicity? An analysis using mammography among low-income women. Health Policy. 2001; 58(3):275-88. DOI: 10.1016/s0168-8510(01)00177-4. View

11.

Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L . Willingness to pay for a cure of low-risk melanoma patients in Germany. PLoS One. 2018; 13(5):e0197780. PMC: 5967822. DOI: 10.1371/journal.pone.0197780. View

12.

Bernard M, Brignone M, Adehossi A, Pefoura S, Briquet C, Chouaid C . Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study. Lung Cancer. 2010; 72(1):114-8. DOI: 10.1016/j.lungcan.2010.07.004. View

13.

Lemos S, Halstead J, Mohr R, Susca P, Woodward R . Valuing the Cancer Mortality Risk Reduction from Lowering the Arsenic Maximum Contaminant Level in New Hampshire Municipal Water Supplies. Environ Manage. 2020; 65(6):725-736. DOI: 10.1007/s00267-020-01288-3. View

14.

Soekhai V, de Bekker-Grob E, Ellis A, Vass C . Discrete Choice Experiments in Health Economics: Past, Present and Future. Pharmacoeconomics. 2018; 37(2):201-226. PMC: 6386055. DOI: 10.1007/s40273-018-0734-2. View

15.

Garcia L, Cerda A . Contingent assessment of the COVID-19 vaccine. Vaccine. 2020; 38(34):5424-5429. PMC: 7315946. DOI: 10.1016/j.vaccine.2020.06.068. View

16.

Bridges J . Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2004; 2(4):213-24. View

17.

Yasunaga H . Willingness to pay for mass screening for prostate cancer: a contingent valuation survey. Int J Urol. 2008; 15(1):102-5. DOI: 10.1111/j.1442-2042.2007.01931.x. View

18.

Igarashi A, Goto R, Yoneyama-Hirozane M . Willingness to pay for QALY: perspectives and contexts in Japan. J Med Econ. 2019; 22(10):1041-1046. DOI: 10.1080/13696998.2019.1639186. View

19.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

20.

Smith T, Hillner B, Desch C . Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993; 85(18):1460-74. DOI: 10.1093/jnci/85.18.1460. View